The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and ...

To address these shortcomings, we introduce SymPcNSGA-Testing (Symbolic execution, Path clustering and NSGA-II Testing), a ...

Platform combines proprietary AI sequence optimization, novel genetic parts, and lab validation in application-relevant cell models to improve expression and half-life, delivering top candidates in ...

The simulator takes into account forecasted demand in each region, transportation costs, and the operational capacity of each warehouse.

The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and projected to reach US$ 1,081.9 million ...

Funding will expand the range of Dualase(R) genome editors for new high morbidity and mortality genetic disease targets. TORONTO, March 18, 2026 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a ...

Think of FEA as the ultimate GPS for government agencies trying to navigate the messy but exciting world of AI without crashing their systems.

Specific Biologics Inc. ("Specific"), a biotechnology company developing industry-leading in vivo genome editing medicines to treat the untreatable, today announced that together with Western ...

Direct prompt injection occurs when a user crafts input specifically designed to alter the LLM’s behavior beyond its intended boundaries.

Long-term lithium therapy remains the most effective maintenance treatment for bipolar disorder, yet it poses a significant risk of progressive renal impairment in a subset of patients. Early ...

Things are changing fast, and a lot of that has to do with new medical technology. As we head into 2026, some really interesting developments are popping up that could change how we do things. We’re ...